| Name | Title | Contact Details |
|---|
Mydecine Innovations Groupā¢ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) is a life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions. Mydecine`s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtionalā¢ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences, Mindleap Health, and NeuroPharm focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.
BioSciConcepts is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
#Cereset is a wellness company that helps their clients relax their #brain to manage stress and achieve restful #sleep. š§ š¤ Centers across the US & Europe.
GenBio is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GeneDx is focused on delivering personalized, actionable insights that improve health outcomes. We sit at the intersection of diagnostics and data science, pairing decades of genomic expertise with an unmatched ability to interpret clinical data at scale. Our exome and genome testing is among the best in the industry. We expect that it will be even more advanced in the future with the help of CentrellisĀ®, our innovative health information platform. Powered by millions of medical records, CentrellisĀ® integrates digital tools with artificial intelligence to ingest and synthesize clinical and genomic data. As a result of our robust test menu, including our exome and genome testing, and the comprehensive insights generated by CentrellisĀ®, we are developing a more complete understanding of complex disease than ever before. This translates to faster diagnosis, more effective treatment plans, and enhanced drug discovery. Our offerings help a whole spectrum of healthcare partners -- clinicians, researchers, health systems, pharmaceutical companies, and payors -- improve patient experiences and advance population health.